AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, today reported fourth quarter and annual results for 2021.
Fourth Quarter 2021 Summary
Strong top line growth across each segment resulted in reported sales up 9% and core sales (excluding currency effects and acquisitions) up 10%
Reported earnings per share increased 8% to $0.85
Adjusted earnings per share (excluding restructuring charges, the unrealized loss on the equity investment and acquisition costs) increased 3% to $0.93
Reported net income increased 8% to $58 million
Adjusted EBITDA increased 3% to $154 million
Annual 2021 Summary
Top line growth across each segment drove record annual sales of $3.2 billion
Reported sales grew 10% and core sales increased 7%
Reported earnings per share increased 12% to $3.61
Adjusted earnings per share increased 4% to $3.88
Reported net income totaled $244 million, exceeding 2019 pre-pandemic levels
Adjusted EBITDA totaled $607 million, exceeding 2019 pre-pandemic levels
Acquired Voluntis, a pioneer in digital therapeutics, and 80% of Weihai Hengyu Medical Products, a leading Chinese manufacturer of elastomeric and plastic components used in injectable drug delivery
Furthered our ESG performance and commitments resulting in the following recognitions: Newsweek’s Most Responsible Companies, Barron’s Most Sustainable Companies, Forbes’ Green Growth 50 list, Forbes’ Global Top 10 Female-Friendly Companies, JUST Capital’s Top 10 Companies Leading in Reducing Environmental Impact, EcoVadis Platinum and CDP’s Supplier Engagement Leaderboard
28th consecutive year of paying increased annual cash dividends
details at: https://www.aptar.com/wp-content/uploads/2022/02/PR-Feb-17-2022-Aptar-Q4-and-Annual-2021-Results.pdf